Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical stage pharmaceutical company specializing in endocrine diseases and tumors, has announced its participation in two upcoming investor conferences in New York this September. The company will engage in fireside chats at:
1. The Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024, at 5:35 p.m. ET
2. The Cantor Global Healthcare Conference on September 18, 2024, at 8:35 a.m. ET
Both events will be webcast live and archived on Crinetics' website. Investors interested in 1x1 meetings with management should contact their conference representatives.
Crinetics Pharmaceuticals (Nasdaq: CRNX), un'azienda farmaceutica in fase clinica specializzata in malattie endocrine e tumori, ha annunciato la sua partecipazione a due prossimi eventi per investitori a New York questo settembre. L'azienda prenderà parte a discussioni informali presso:
1. Il 22° Annual Global Healthcare Conference della Morgan Stanley il 4 settembre 2024, alle 17:35 ET
2. Il Cantor Global Healthcare Conference il 18 settembre 2024, alle 08:35 ET
Entrambi gli eventi saranno trasmessi in diretta e archiviati sul sito web di Crinetics. Gli investitori interessati a incontri individuali con il management dovrebbero contattare i rappresentanti della conferenza.
Crinetics Pharmaceuticals (Nasdaq: CRNX), una empresa farmacéutica en etapa clínica especializada en enfermedades endocrinas y tumores, ha anunciado su participación en dos próximas conferencias para inversores en Nueva York este septiembre. La compañía participará en charlas informales en:
1. La 22ª Conferencia Anual de Atención Médica Global de Morgan Stanley el 4 de septiembre de 2024, a las 5:35 p.m. ET
2. La Conferencia de Atención Médica Global de Cantor el 18 de septiembre de 2024, a las 8:35 a.m. ET
Ambos eventos se transmitirán en vivo y se archivarián en el sitio web de Crinetics. Los inversores interesados en reuniones individuales con la dirección deben contactar a sus representantes de conferencia.
Crinetics Pharmaceuticals (Nasdaq: CRNX)는 내분비 질환 및 종양을 전문으로 하는 임상 단계의 제약 회사로, 이번 9월 뉴욕에서 열리는 두 개의 투자자 컨퍼런스에 참여한다고 발표했습니다. 회사는 다음의 자리에서 열린 대화에 참여할 예정입니다:
1. 모건 스탠리 제22회 연례 글로벌 헬스케어 컨퍼런스가 2024년 9월 4일 오후 5:35 ET에 개최됩니다.
2. 칸토 글로벌 헬스케어 컨퍼런스가 2024년 9월 18일 오전 8:35 ET에 개최됩니다.
두 행사 모두 실시간으로 방송되며 Crinetics 웹사이트에 아카이브됩니다. 경영진과 1:1 미팅에 관심이 있는 투자자는 각 컨퍼런스의 담당자에게 연락해야 합니다.
Crinetics Pharmaceuticals (Nasdaq: CRNX), une entreprise pharmaceutique en phase clinique spécialisée dans les maladies endocrines et les tumeurs, a annoncé sa participation à deux prochaines conférences pour investisseurs à New York ce septembre. La société participera à des discussions informelles lors de :
1. La 22ème Conférence Annuelle Mondiale de la Santé de Morgan Stanley le 4 septembre 2024, à 17h35 ET
2. La Conférence Mondiale de la Santé de Cantor le 18 septembre 2024, à 8h35 ET
Les deux événements seront diffusés en direct et archivés sur le site web de Crinetics. Les investisseurs intéressés par des réunions individuelles avec la direction doivent contacter leurs représentants de conférence.
Crinetics Pharmaceuticals (Nasdaq: CRNX), ein pharmazeutisches Unternehmen in klinischer Phase, das sich auf endokrine Erkrankungen und Tumore spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen in New York im September bekannt gegeben. Das Unternehmen wird an informellen Gesprächen teilnehmen:
1. Der 22. jährlichen globalen Gesundheitskonferenz von Morgan Stanley am 4. September 2024 um 17:35 Uhr ET
2. Der Cantor Global Healthcare Conference am 18. September 2024 um 8:35 Uhr ET
Beide Veranstaltungen werden live übertragen und auf der Website von Crinetics archiviert. Investoren, die an 1x1-Gesprächen mit dem Management interessiert sind, sollten ihre Konferenzvertreter kontaktieren.
- None.
- None.
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that company management will participate in fireside chats at the Morgan Stanley 22nd Annual Global Healthcare Conference and the Cantor Global Healthcare Conference both being held in New York, NY in September.
Morgan Stanley 22nd Annual Global Healthcare Conference
Fireside chat on Wednesday, September 4, 2024 at 5:35 p.m. Eastern Time
Webcast link HERE
Cantor Global Healthcare Conference
Fireside chat on Wednesday, September 18, 2024 at 8:35 a.m. Eastern Time
Webcast link HERE
The live and archived webcasts will be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at www.crinetics.com/events.
If you are interested in arranging a 1x1 meeting with management, please contact your conference representative.
ABOUT CRINETICS PHARMACEUTICALS
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is an investigational, first-in-class, oral, once-daily somatostatin receptor type 2 (SST2) agonist in Phase 3 clinical development for acromegaly and in Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant (CRN04894), an investigational, first-in-class, oral ACTH antagonist, that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075
FAQ
When is Crinetics Pharmaceuticals (CRNX) participating in the Morgan Stanley Healthcare Conference?
What is the date and time for Crinetics Pharmaceuticals' (CRNX) fireside chat at the Cantor Global Healthcare Conference?
Where can investors access the webcasts of Crinetics Pharmaceuticals' (CRNX) conference presentations?
How can investors arrange 1x1 meetings with Crinetics Pharmaceuticals' (CRNX) management at these conferences?
